Skip to main content

Table 2 Autotransplanted patients

From: Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts

Patient Age Diagnosisa Status at transplantb Source of graftc Conditioning regimend Relapse (days) Last follow up (days) Status at last follow up Cause of death
187 60 AML 1st CR PB IBU 305 426 Dead Relapse/Progression
188 19 DLBCL 1st PR PB BEAM no 1159 Alive  
189 25 NHL 1st CR PB BEAM no 1152 Alive  
190 50 HL 2nd CR PB BEAM no 1149 Alive  
191 51 MM 1st PR PB MEL200 861 1239 Dead Relapse/Progression
  1. aAML, Acute Myeloid Leukemia; DLBCL, Diffuse Large B Cell Lymphoma; NHL, Non-Hodgkin’s Lymphoma; HL, Hodgkin’s Lymphoma; MM, multiple myeloma
  2. bCR, complete remission; PR, partial remission
  3. cPB: CD34 peripheral blood autologous stem cells
  4. dBEAM: Carmustine, Etoposide, Cytarabine, Melphalan; IBU: Idarubicine, Busulphan; MEL200: Melphalan